cerrar
Tagged with IOT

Company Spotlight: I-Mab Biopharma
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced…

Zaiqi Wang – Chairman & CEO, InxMed, China
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment,…

HKEX SVP Reflects on Two Years of Pre-Revenue Biotech IPO…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as…

Company Spotlight: Zai Lab, China
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in…

Hong Kong Biotech IPOs since Listing Reform in April 2018
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech…

Jin LI – Chairman & CEO, HitGen, China
Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the…

China Pharma News Roundup July 14th 2020
A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for…

Six Indian Companies at the Forefront of COVID-19 Vaccine…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving…

China Pharma News Roundup June 29th 2020
The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between…

CanSinoBIO: China’s Leading COVID-19 Vaccine Developer…
Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of…

Jisoo Pae – CEO, Genome & Company
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO,…

Korean Corestem Targets US Market for Ground-Breaking ALS…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here